• 1. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 2. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 3. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 4. Alt-proteins: A promising future
• 5. Aluminium complexes with thio-phosphorus ligands: syntheses and characterisations of [Al2(CyPS3)2(CyPHS2)2] and [Al(S2PPh2)3]?
  Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. White Dalton Trans., 2008, 5705-5707

Introduction to (2,4-Dimethyl-1,3-thiazol-5-yl)methylamine dihydrochloride (CAS No. 1185293-90-6)

(2,4-Dimethyl-1,3-thiazol-5-yl)methylamine dihydrochloride, identified by its CAS number 1185293-90-6, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This compound belongs to the thiazole derivatives, a class of heterocyclic compounds known for their diverse biological activities and applications in medicinal chemistry. The structural features of this molecule, particularly the presence of a thiazole ring substituted with methyl groups at the 2 and 4 positions and an amine group at the 5 position, contribute to its unique chemical properties and potential biological functions.

The< strong>dihydrochloride salt form of this compound enhances its solubility in water, making it more suitable for various biochemical assays and pharmaceutical formulations. The thiazole core is a privileged scaffold in drug discovery due to its ability to interact with multiple biological targets. Recent studies have highlighted the therapeutic potential of thiazole derivatives in treating a range of diseases, including infections, inflammation, and neurological disorders.

In recent years, researchers have been exploring the pharmacological properties of< strong>(2,4-Dimethyl-1,3-thiazol-5-yl)methylamine dihydrochloride. One of the most promising areas of research is its potential as an antimicrobial agent. The thiazole ring has been shown to disrupt bacterial cell membranes and inhibit key enzymatic pathways essential for bacterial survival. Preliminary studies have demonstrated that this compound exhibits significant activity against Gram-positive bacteria, making it a candidate for developing new antibiotics.

Furthermore, the< strong>methylamine moiety in the structure suggests possible applications in central nervous system (CNS) drug development. Methylamine derivatives have been investigated for their role in modulating neurotransmitter systems. The combination of the thiazole ring and the methylamine group in< strong>(2,4-Dimethyl-1,3-thiazol-5-yl)methylamine dihydrochloride may provide a unique mechanism of action in treating neurological disorders such as depression and anxiety.

The< strong>hydrochloride form of this compound ensures high stability and bioavailability, which are crucial factors for pharmaceutical applications. The salt form improves the compound's solubility in aqueous solutions, facilitating its use in various formulations including oral tablets, injectables, and topical treatments. This property makes it a versatile candidate for further development in both preclinical and clinical studies.

Recent advancements in computational chemistry have also contributed to a deeper understanding of the interactions between< strong>(2,4-Dimethyl-1,3-thiazol-5-yl)methylamine dihydrochloride and biological targets. Molecular docking studies have identified potential binding sites on enzymes and receptors relevant to inflammation and infection pathways. These findings provide valuable insights for designing more effective derivatives with enhanced pharmacological properties.

The synthesis of< strong>(2,4-Dimethyl-1,3-thiazol-5-yl)methylamine dihydrochloride involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. The synthesis typically starts with the condensation of appropriate precursors to form the thiazole ring followed by functionalization at the 2 and 4 positions with methyl groups. The introduction of the methylamine group at the 5 position is achieved through nucleophilic substitution reactions. Finally, conversion to the dihydrochloride salt is carried out to enhance solubility and stability.

The chemical properties of this compound make it an interesting subject for further investigation in various fields. Its ability to interact with multiple biological targets suggests potential applications beyond antimicrobial therapy. For instance, its structural similarity to known CNS active compounds makes it a candidate for developing new treatments for neurological disorders.

In conclusion,< strong>(2,4-Dimethyl-1,3-thiazol-5-yl)methylamine dihydrochloride (CAS No. 1185293-90-6) is a promising compound with diverse biological activities. Its unique structural features and favorable physicochemical properties make it an attractive candidate for further research and development in pharmaceuticals. As our understanding of its pharmacological effects continues to grow, this compound holds significant potential for addressing various therapeutic challenges.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)